Site Editor

Al B. Benson III, MD, FACP, FASCO

Advertisement
Advertisement
t

Ghassan K. Abou-Alfa, MD, on Clinical Implications of Using Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma

Posted: Friday, September 30, 2022

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses findings from the HIMALAYA trial, which showed that tremelimumab plus durvalumab is superior to sorafenib for patients with unresectable hepatocellular carcinoma and may change the future standard of care in this setting. Dr. Abou-Alfa also examines the question of how best to prevent and manage adverse events associated with immunotherapies.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.